Table 3.
Change between baseline and nadir of body weight and blood cells counts between CHB and CHC patients with Peg-IFN-based therapy
| 24 weeks | 48 weeks | |||||
|---|---|---|---|---|---|---|
| CHB | CHC | P | CHB | CHC | P | |
| Peg-IFN and ribavirin associated | ||||||
| BW (kg) | −1.99 ± 1.79 (−3 ± 3%) | −4.4 ± 2.9 (−6 ± 4%) | <0.0001* | −3.28 ± 2.11 (−5 ± 3%) | −6.46 ± 3.23 (−9 ± 4%) | <0.0001* |
| Hb (g/dL) | −1.8 ± 0.84 (−12 ± 5%) | −3.8 ± 1.7 (−25 ± 11%) | <0.0001* | −2.59 ± 0.84 (−17 ± 5%) | −4.26 ± 1.65 (−28 ± 10%) | <0.0001* |
| Peg-IFN associated | ||||||
| WBC (μL) | −2,896.79 ± 1,362.05 (−46 ± 15%) | −3,508.71 ± 1,464.69 (−56 ± 13%) | 0.011* | −3,337.2 ± 1,166.71 (−54 ± 10%) | −3,529.06 ± 1,112.69 (−6 ± 12%) | 0.497 |
| PLT (1,000 μL−1) | −84.23 ± 41.55 (−43 ± 17%) | −64.27 ± 35.91 (−33 ± 17%) | 0.002* | −83.32 ± 35.4 (−46 ± 15%) | −69.82 ± 43.42 (−37 ± 19%) | 0.188 |
| ANC (μL) | −1,881.89 ± 936.77 (−57 ± 19%) | −2,054.75 ± 983.86 (−65 ± 14%) | 0.303 | −2,044.12 ± 814.89 (−61 ± 14%) | −1,992.91 ± 659.02 (−67 ± 11%) | 0.777 |
BW body weight, Hb hemoglobin, WBC white blood cell, PLT platelet, ANC absolute neutrophil count
* Statistically significant